| Julianne W Childs, DO | |
|
210 S Shore Rd, Suite 106, Marmora, NJ 08223-1200 | |
| (609) 390-7888 | |
| (609) 390-2614 |
| Full Name | Julianne W Childs |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 38 Years |
| Location | 210 S Shore Rd, Marmora, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639166101 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | MB052916 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cape Regional Home Health Care, Llc | Cape may court house, NJ | Home health agency |
| Cape Regional Medical Center Inc | Cape may court house, NJ | Hospital |
| Shore Medical Center | Somers point, NJ | Hospital |
| Inspira Medical Center Vineland | Vineland, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional Cancer Care Associates Llc | 5294710091 | 104 |
News Archive
A research team led by Dr. Tony Lam at the Toronto General Research Institute and the University of Toronto discovered a novel function of a hormone found in the gut that might potentially lower glucose levels in diabetes.
The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis, if the drug is administered to certain patients with kidney disease.
According to scientists in the U.S. people who keep fit by running when they are middle aged and older, are less likely to become disabled later in life and may live longer.
As early as one week after beginning treatment for brain tumors, a new imaging analysis method was able to predict which patients would live longer, researchers from the University of Michigan Comprehensive Cancer Center have found.
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
› Verified 7 days ago
| Entity Name | Regional Cancer Care Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801850243 PECOS PAC ID: 5294710091 Enrollment ID: O20040623001494 |
News Archive
A research team led by Dr. Tony Lam at the Toronto General Research Institute and the University of Toronto discovered a novel function of a hormone found in the gut that might potentially lower glucose levels in diabetes.
The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis, if the drug is administered to certain patients with kidney disease.
According to scientists in the U.S. people who keep fit by running when they are middle aged and older, are less likely to become disabled later in life and may live longer.
As early as one week after beginning treatment for brain tumors, a new imaging analysis method was able to predict which patients would live longer, researchers from the University of Michigan Comprehensive Cancer Center have found.
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julianne W Childs, DO 210 S Shore Rd, Suite 106, Marmora, NJ 08223-1200 Ph: (609) 390-7888 | Julianne W Childs, DO 210 S Shore Rd, Suite 106, Marmora, NJ 08223-1200 Ph: (609) 390-7888 |
News Archive
A research team led by Dr. Tony Lam at the Toronto General Research Institute and the University of Toronto discovered a novel function of a hormone found in the gut that might potentially lower glucose levels in diabetes.
The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis, if the drug is administered to certain patients with kidney disease.
According to scientists in the U.S. people who keep fit by running when they are middle aged and older, are less likely to become disabled later in life and may live longer.
As early as one week after beginning treatment for brain tumors, a new imaging analysis method was able to predict which patients would live longer, researchers from the University of Michigan Comprehensive Cancer Center have found.
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
› Verified 7 days ago
Kaleem Ahmad, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 210 S Shore Rd, Suite 106, Marmora, NJ 08223 Phone: 609-390-7888 Fax: 609-390-2614 | |
Dr. Avelino Cruz, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 60 Tuckahoe Rd, Marmora, NJ 08223 Phone: 609-390-2632 Fax: 609-390-9210 | |
Ms. Tiffany Pompa, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 210 S Shore Rd Ste 106, Marmora, NJ 08223 Phone: 609-390-7888 Fax: 609-390-2614 | |
Hemang U Dave, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 210 S Shore Rd, Suite 106, Marmora, NJ 08223 Phone: 609-390-7888 Fax: 609-390-2614 |